Assessment of select HER2-negative metastatic breast cancer (mBC) agents as a proxy to understand health technology assessment bodies uncertainties in HER2-low mBC agents in Germany, France, Spain, Italy and England
CANCER RESEARCH（2022）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined